Vivani Medical, Inc. VANI
Regular-session close
After hours · Nov 19, 4:45 PM ET
- YTD
- -11.38%
- 1 year
- -20.44%
- Market cap
- 98.32M
- EPS (ttm)
- -0.35
- Shares out
- 59.23M
- Forward P/E
- -2.11
- YTD return
- -11.38%
- 1-year return
- -20.44%
- 50-day average
- 1.30
- 200-day average
- 1.46
- Enterprise value
- 74.69M
- Volume
- 210.78K
- Avg volume
- 221.85K
- Open
- 1.06
- Previous close
- 1.05
- Day's range
- 1.06 – 1.13
- 52-week range
- 0.80 – 1.66
- Beta
- 3.52
- Analysts
- Buy
- Price target
- 5.50 (+404.6%)
Key statistics
- Price / book
- 2.90
- Free cash flow
- -14.29M
- Total cash
- 24.92M
- Total debt
- 20.04M
- Return on equity
- -86.10%
- Short % of float
- 2.50%
Fundamental scorecard
4 of 25 checks passed on VANI’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.12 | — | — |
| Mar 26, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.13 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.13 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 5, 2022 | ThinkEquity | init | — | Buy |
About Vivani Medical, Inc.
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vivani.com
News
Vivani Medical Announces Private Placement Equity Financing
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects Vivani Medical Q3 EPS $(0.08), Inline
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
Vivani Medical Announces Participation in Upcoming Investor Conferences
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Your note
Sign in to keep a note on VANI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOLCK JOACHIM EBERHARD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 2, 2023 | 0 |
| DWYER DONALD | Officer | Purchase | Oct 2, 2024 | 50,000 |
| LARSON ALEXANDRA L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Apr 17, 2023 | 2,166 |
| MAKES BRIGID A | Chief Financial Officer | Purchase | Dec 17, 2023 | 15,000 |
| MENDELSOHN AARON | Director | Purchase | Jun 8, 2023 | 188,170 |
| MENDELSOHN ADAM | Chief Executive Officer | Stock Gift | Feb 7, 2023 | 3,605,020 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 3.59% | 2,128,042 | 2.51M | Sep 29, 2024 |
| Tanager Wealth Management LLP | 2.20% | 1,303,000 | 1.54M | Sep 29, 2024 |
| Vanguard Group Inc | 1.63% | 967,398 | 1.14M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.58% | 342,891 | 404.61K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.56% | 330,530 | 390.02K | Sep 29, 2024 |
| Monetary Management Group, Inc. | 0.33% | 193,977 | 228.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.07% | 636,702 | 751.31K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.53% | 314,417 | 371.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 175,612 | 207.22K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 51,787 | 61.11K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.08% | 47,980 | 56.62K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 41,496 | 48.97K | Oct 30, 2024 |
